Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

		· · · · · · · · · · · · · · · · · · ·		Application Number			10534210		
			Filing Date			2006-03-17			
INFORMATION DISCLOSURE				First Named Inventor Salas					
STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)				Art Unit		1656			
			.99)	Examiner Nan	ne	Not ye	ret assigned		
				Attorney Docket Number			4408-P03626US00		
				<u> </u>					
				U.S.P	ATENTS				
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	ו בזבוו בווססוו	Name of of cited [		tee or Applicant ent	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	

If you wish to add additional U.S. Patent citation information please click the Add button.

U.S.PATENT APPLICATION PUBLICATIONS								
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publication Date	L NIAMAA AT WATANTAA AR AANIMAANT I	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear		

			FOF	REIGN PAT	ENT DOCUM	MENTS		
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup> j	Kind Code <sup>4</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T5
	1							

## **NON-PATENT LITERATURE DOCUMENTS**

Examiner Cite Initials\*

Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.

**T**5

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

( Not for submission under 37 CFR 1.99)

Application Number		10534210				
Filing Date		2006-03-17				
First Named Inventor	Salas					
Art Unit		1656				
Examiner Name	Not ye	et assigned				
Attorney Docket Numb	er	4408-P03626US00				

1	Thomas, I., et al., (Jul. 2002) "Skipping in a hybrid polyketide synthase: evidence for ACP-to-ACP chain transfer," Chem. Biol. 9:781-787.	
2	Tsuchiya, E., et al., (Jan. 2001) "Borrelidin inhibits a cyclin-dependent kinase (CDK), Cdc28/Cln2, of Saccharomyces cerevisiae," J. Antibiot. 54:84-90.	
3	Wakasugi, K., et al., (Jan. 8, 2002) "A human aminoacyl-tRNA synthetase as a regulator of angiogenesis," Proc. Nat. Acad. Sci. USA 99:173-177.	
4	Wakabayashi, T., et al., (Aug. 1997) "Borrelidin is an angiogenesis inhibitor; disruption of angiogenic capillary vessels in a rat aorta matrix culture model," J. Antibiot. 50:671-676.	
5	Waldron, C., et al., (2001) "Cloning and analysis of the spinosad biosynthetic gene cluster of Saccharopolyspora spinosa," Chem. Biol. 8:487-499.	
6	Wilkinson, B., et al., (Jan. 14, 2000) "Novel octaketide macrolides related to 6-deoxyerythronolide B provide evidence for iterative operation of the erythromycin polyketide synthase," Chem. Biol. 7:111-117.	
7	Wu, N., et al., (Jul. 11, 2001) "Assessing the balance between protein-protein interactions and enzyme-substrate interactions in the channeling of intermediates between polyketide synthase modules," J. Am. Chem. Soc. 123: 6465-6474.	
8	Xue, Y.Q., et al., (Oct. 1998) "A gene cluster for macrolide antibiotic biosynthesis in Streptomyces venezuelae: architecture of metabolic diversity," Proc. Nat. Acad. Sci. USA 95:12111-12116.	
9	Xue, Y.Q., et al., (Feb. 2000) "Alternative modular polyketide synthase expression controls macrolactone structure," Nature 403:571-575.	
10	Bentley S.D., et al. (May 9, 2002) "Complete genome sequence of the model actinomycetes Streptomyces coelicolor A3(2)," Nature 417:141-147.	
11	KUO, M.S., et al., "Assignment of 1H and 13C NMR signals and the alkene geometry at C-7 in borrelidin," J. of Antibiotics, 42(6):1006-1007 (June 1989).	

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

( Not for submission under 37 CFR 1.99)

Application Number		10534210			
Filing Date		2006-03-17			
First Named Inventor	Salas				
Art Unit		1656			
Examiner Name	Not ye	et assigned			
Attorney Docket Numb	er	4408-P03626US00			

	12	FUNAHASHI, Y., et al., "Establishment of a quantitative mouse dorsal air sac model and its application to evaluate a new angiogenesis inhibitor," Oncology Research 11:319-29 (1999).								
	13	HADDAD, N., et al., "Studies towards total synthesis of borrelidin, regioselective methylation of bis-epoxides and structure determination," Tetrahedron Letters, 38(34):6079-6082 (1997).								
	14	HADDAD, N., et al., "Studies towards total synthesis of borrelidin, stereoselective synthesis of the polysubstituted macrolidic part," Tetrahedron Letters, 38(34):6075-6078 (1997).								
If you wis	sh to a	add add	ditional non-patent literature document citation information please	e click the Add b	outton					
			EXAMINER SIGNATURE							
Examine	r Sign	ature	Date	e Considered						
citation if	f not in  Codes  T.3). 3	of USPT	reference considered, whether or not citation is in conformance remance and not considered. Include copy of this form with next of the Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. <sup>2</sup> Enter office that anese patent documents, the indication of the year of the reign of the Emperor managements.	communication issued the document	to applicant.  nt, by the two-letter code (Wrial number of the patent doc	ument.				
			appropriate symbols as indicated on the document under WIPO Standard ST.16 on is attached.	if possible. <sup>5</sup> Applic	cant is to place a check mark	chere it				

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

( Not for submission under 37 CFR 1.99)

Application Number		10534210			
Filing Date		2006-03-17			
First Named Inventor Salas					
Art Unit		1656			
Examiner Name	Not ye	et assigned			
Attorney Docket Numb	er	4408-P03626US00			

		CERTIFICA	ATION STATEMENT						
Please	see 37 CFR 1	.97 and 1.98 to make the appropriate s	selection(s):						
fro	That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).								
OR									
for aft	reign patent o ter making rea y individual d	information contained in the informatice in a counterpart foreign application in the information is a counterpart foreign application in the information is a counterpart foreign application in the information is a counterpart for information in the information is applicated in a counterpart for information in the information is applicated in a counterpart for information in the information	on, and, to the knowledge of the contained in the information d	ne person signing the certification isclosure statement was known to					
☐ Se	e attached ce	rtification statement.							
☐ Fe	e set forth in 3	37 CFR 1.17 (p) has been submitted he	erewith.						
A signa	one ature of the ap the signature.	plicant or representative is required in	IGNATURE accordance with CFR 1.33, 10.	18. Please see CFR 1.4(d) for the					
Signatu	ıre	/RCN/	Date (YYYY-MM-DD)	2007-09-06					
Name/F	Print	Robert C. Netter, Jr., Ph.D., J.D.	Registration Number	56,422					
	11 a a 41 a a a a 41 a 4	rmation is required by 37 CEP 1.07 and	d 4 00. The information is requi	rod to obtain or rotain a honofit by the					

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**